Loading, Please Wait...
HENDERSON, Nev., Aug. 28, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose that is patented through Oct 2029 (US Patent 8,857,874 Oct 2015), for the healthcare and wound care sectors, today announces that the last patient has completed their follow up patient study visit in the HemoStyp Human Clinical Trial. This trial was conducted on 236 WIRB (Western Institutional Review Board) approved and consented patients. Surgeries consisted of Level 1 and Level 2 bleeds on the Lewis bleeding scale for abdominal, cardiovascular, thoracic and vascular surgeries. The patient study follow up occurs 21-40 days after the respective surgery. This is done to confirm there are no post-operative complications or related product issues. The study is a randomized trial with safety and efficacy endpoints for FDA (Food and Drug Administration) PMA Class III submission. All clinical trial post-operative follow ups have been completed and data analysis and PMA submission to the FDA will occur imminently.
The Company is continuing its discussions with well positioned candidates interested in acquisition of the Company or partnerships that allow penetration into the surgical markets.
About United Health Products
United Health Products develops technology, manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
United Health Products, Inc.
PAN Consultants Ltd.
Philippe Niemetz 212-344-6464 firstname.lastname@example.org